



PHARMACEUTICAL 2018











PHARMACEUTICAL 2018



DURECT CORP Rank 52 of 349



The relative strengths and weaknesses of DURECT CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DURECT CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 527% points. The greatest weakness of DURECT CORP is the variable Research and Development, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 353% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	45,358
Cost of Goods Sold	0
Intangible Assets	6,399
Liabilities, Current	15,828
Liabilities, Non-Current	0
Other Assets	427
Other Compr. Net Income	2.0
Other Expenses	6,633
Other Liabilities	0
Other Net Income	-1,458
Property and Equipment	929
Research and Development	31,609
Revenues	49,170
Selling, General and Administrative Expense	13,165

Output Variable	Value in 1000 USD
Assets	53,113
Liabilities	15,828
Expenses	51,407
Stockholders Equity	37,285
Net Income	-3,695
Comprehensive Net Income	-3,694
Economic Capital Ratio	75%